Pharmacotherapy for chronic gastro-oesophageal reflux disease and Barrett's oesophagus

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 7, 2003, Pages 1049-1061

  Wurm, Peter ^a   de Caestecker, John ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Alginates; Antacids; Barrett's oesophagus; Domperidone; Gastro oesophageal reflux disease; H2 receptor antagonist; Metoclopramide; Non erosive reflux disease; Oesophagitis; Proton pump inhibitor

Indexed keywords

ALGINIC ACID; ANTACID AGENT; CIMETIDINE; CISAPRIDE; DOMPERIDONE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE; THEOPHYLLINE; WARFARIN;

ABDOMINAL CRAMP; ANGIONEUROTIC EDEMA; BARRETT ESOPHAGUS; BRONCHOSPASM; CLINICAL TRIAL; CONSTIPATION; DENTAL CARIES; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESPONSE; ESOPHAGITIS; FLATULENCE; GALACTORRHEA; GASTROESOPHAGEAL REFLUX; GYNECOMASTIA; HEADACHE; HEALING; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERCALCEMIA; HYPERNATREMIA; HYPERPROLACTINEMIA; LIFESTYLE; LIVER TOXICITY; LONG QT SYNDROME; LONG TERM CARE; METABOLIC ALKALOSIS; NAUSEA AND VOMITING; NEUROTOXICITY; RESTLESSNESS; REVIEW; STOMACH ACID; VERTIGO; VISUAL IMPAIRMENT;

EID: 0038783543     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.7.1049     Document Type: Review

References (112)

1. THOMPSON WG, HEATON KW: Heartburn and globus in apparently healthy people. Can. Med. Assoc. J. (1982) 126:46-48.
2. LOCKE GR, TALLEY NJ, FETT SL, ZINSMEISTER AR, MELTON LJ: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 112:1448-1456.
3. MITTAL RK, BALABAN DH: Mechanisms of disease: the esophagogastric junction. N. Engl. J. Med. (1997) 336:924-932.
4. MITTAL RK, LANGE RC, MCCALLUM RW: Identification and mechanisms of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology (1987) 92:130-135.
5. VAN HERWAARDEN MA. SAMSOM M, SMOUT AJPM: Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroentervology (2000) 119:1439-1446.
6. BREEN KJ, WHELAN G: The diagnosis of reflux oesophagitis: an evaluation of five investigative procedures. Aust. NZ J. Surg. (1978) 48:156-161.
7. KAHRILAS PJ, DODDS WJ, HOGAN WJ, KERN M, ARNDORFER RC, REECE A: Esophageal peristaltic dysfunction in peptic oesophagitis. Gastroenterology (1986) 91:897-904.
8. IASCONE C, DEMEESTER TR, LITTLE AG, SKINNER DB: Barrett's oesophagus functional assessment, proposed pathogenesis, and surgical therapy. Arch. Surg. (1983) 118:543-549.
9. CASTELL DO: Gastroesophageal reflux disease: is it a motility disorder? In: Advances in drug therapy of gastroesophageal reflux disease. Front Gastrointest. Res. Scarpignato C (Ed.), Basel Karger, Basel, Switzerland (1992) Vol. 20.
10. RICHTER JE: Importance of bile reflux in Barrett's esophagus. Dig. Dis. (2000)18:8-16.
11. SAVARY M, MILLER G: The oesophagus. Handbook and atlas of endoscopy. Gassman AG, Solothorn, Switzerland (1978).
12. ARMSTRONG D, MONNIER P, NICOLET M, BLUM AL, SAVARY M: Endoscopic assessment of oesophagitis. Gullet (1991) 1:63-67.
13. LUNDELL LR, DENT J, BENNETT JR et al.: Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut (1999) 45:172-180.
14. HARVEY RF, GORDON PC, HADLEY N et al.: Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet (1987) 2:1200-1203.
15. LAGERGREN J, BERGSTRÖM R, NYRÉN O: No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study. Gut (2000) 47:26-29.
16. GRAHAM DY, SMITH JL, PATTERSON DJ: Why do apparently healthy people use antacid tablets? Am. J. Gastroenterol. (1983) 78:257-260.
17. SCARPIGNATO C, GALMICHE J-P: Antacids and alginates in the treatment of gastroesophageal reflux disease. In: Front Gastrointest. Res., Basel, Karger (1992) 20:153-181.
18. SCARPIGNATO C: Sucralfate and other mucosal protective compounds: pharmacology and potential in the treatment of esophageal lesions. In: Front Gastrointest. Res., Basel, Karger (1992) 20:317-346.
19. WEISS W, BRUNNER H, BUTTNER G et al.: Therapie der Reflux-Ösophagitis mit Sucralfat. Dtsch. Med. Wochensch. (1984) 108:1706-1711.
20. CARLING L, CRONSTEDT J, ENGQUIST A et al.: Sucralfate versus placebo in reflux esophagitis. A double-blind multicenter study. Scand. J. Gastroenterol. (1988) 23:1117-1124.
21. STURM A, HOLTMANN G, GOEBELL H, GERKEN G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion (1999) 60:422-427.
22. SCHULZE-DELRIEU K: Metoclopramide. Gastroenterology (1979) 77:768-779.
23. SCHUURKES JAJ, VAN NUETEN JM: Dose-dependant stimulation of antroduodenal coordination by domperidone via specific dopamine-receptors. Arch. Int. Pharmacol. Ther. (1982) 256:311-314.
24. GUSLANDI M, TESTONI PA, PASSARETTI S et al.: Ranitidine vs. Metoclopramide in the medical treatment of reflux oesophagitis. Hepat. Gastroenterol. (1983) 30:96-98.
25. VALENZUELA JE: Effects of domperidone on the symptoms of reflux oesophagitis. Progress with Domperidone. Royal Society of Medicine, International Congress and Symposium Series (1981) 36:51.
26. ROBINSON OPW: Metoclopramide side effects and safety. Postgrad. Med. (1973) 49(Suppl. 4):77-80.
27. SCHUURKES JAJ, VAN NUETEN JM, VAN DAELE PGH, REYNTJENS AJ, JANSSEN PAJ: Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. J. Pharmacol. Exp. Ther. (1985) 234:775-783.
28. WISEMAN LR, FAULDS D: Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs (1994) 47:116-152.
29. DE CAESTECKER J: Prokinetics and reflux a promise unfulfilled. Eur. J. Gastroenterol. Hepatol. (2002) 14:5-7.
30. BLUM AL, ADAMI B, BOUZO MH et al.: Effect of cisapride on relapse of oesophagitis: a multinational, placebo controlled trial in patients healed with an antisecretory drug. Dig. Dis. Sci. (1993) 38:551-560.
31. TYTGAT GN, ANKER-HANSEN O, CARLING L et al.: Effect of cisapride on relapse of reflux oesophagins, healed with antisecretory drugs. Scand J. Gastroenterol. (1992) 27:175-183.
32. HATLEBAKK JG, JOHNSSON F, VILIEN M, CARLING L, WETTERHUS S, THOGERSEN T: The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. Scand. J. Gastroenterol. (1997) 32:1100-1106.
33. VIGNERI S, TERMINI R, LEANDRO G et al.: A comparison of five maintenance therapies for reflux esophagitis. N. Engl. J. Med. (1995) 333:1106-1110.
34. TONINI M, DE PONTI F, DI NUCCI A, CREMA F: Review article: cardiac adverse effects of gastrointestinal prokinetics. Alim. Pharmacol. Ther. (1999) 13:1585-1591.
35. 2-receptor antagonists in the era of proton pump inhibitors. In: Guidelines for management of symptomatic gastro-oesophageal reflux disease. Lundell L (Ed.), Science Press, London, UK (1998):55-66.
36. BAUMANN JH, KIMMELBLATT BJ, CARACCIO TR, SILVERMAN HM, SIMON GI, BECK GJ: Cimetidine-theophylline interaction: report of four patients. Ann. Allergy (1982) 48:100-107.
37. SERLIN MJ, SIBEON RG, MOSSMAN S, BRECKENRIDGE AM: Cimetidine: interaction with oral anticoagulants in men. Lancet (1979) 2:317-319.
38. ORR WC, ROBINSON MG, HUMPHRIES TJ, ANTONELLO J, CAGLIOLA A: Dose response effect of famotidine on patterns of gastro-esophageal reflux. Aliment. Pharmacol. Ther. (1988) 2:229-235.
39. TYTGAT GNJ, NICOLAI JJ, REMAN FC: Efficacy of different doses of cimetidine in the treatment of reflux oesophagitis. A review of three large double blind controlled trials. Gastroenterology (1990) 99:629-634.
40. CLOUD M, OFFEN W: Nizatidine 150 mg b.i.d. relieves symptoms and decreases severity of oesophagitis in gastroesophageal reflux disease. Gastroenterology (1989) 96:A91.
41. HALVORSEN L, LEE FI, WESDORPICE, JOHNSON NJ, MILLS JG, WOOD JR: Acute treatment of reflux oesophagitis: a multicentre study to compare 150 mg ranitidine twice daily with 300 mg ranitidine at bedtime. Aliment. Pharmacol. Ther. (1989) 3:171-181.
42. BOVERO E, CHELI R, BARBARA L et al.: Short-term treatment of reflux oesophagitis with ranitidine 300 mg nocte. Italian multicentre study. Hepato-gastroenterology (1987) 34:155-159.
43. ROUFAIL W, BELSITO A, ROBINSON M, BARISH C, RUBIN A: Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Glaxo Erosive Esophagitis Study Group. Alim. Pharmacol. Ther. (1992) 6:597-607.
44. SIMON TJ, BERLIN RG, TIPPING R, GILDE L: Efficacy of twice daily dose of 40 or 20 mg famotidine or 150 mg ranitidine for treatment of patients with moderate or severe erosive oesophagitis. Scand. J. Gastroenserol. (1993) 28:375-380.
45. SIMON TJ, BERENSON MM, BERLIN AG, SNAPINN S, CAGLIOILA A: Randomized, placebo-controlled comparison of famotidine 20 mg b.i.d. or 40 mg b.i.d. in patients with erosive oesophagitis. Aliment. Pharmacol. Ther. (1994) 8:71-79.
46. WESDORP ICE, DEKKER W, FESTEN HPM: Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux oesophagitis. Dig. Dis. Sci. (1993) 38:2287-2293.
47. SHERBANIUK R, WENSEL R, BAILEY R et al.: Ranitidine in the treatment of symptomatic gastroesophageal reflux disease. J. Clin. Gastroenterol. (1984) 4:9-15.
48. KOELZ HR, BIRCHLER R, BRETHOLZ A et al: Healing and relapse of reflux oesophagitis during treatment with ranitidine. Gastroenterology (1986) 91:1198-1205.
49. BERLIN RG, EBEL D, COOK T: International oesophagitis study group. Famotidine 20 mg hs and 40 mg hs versus placebo in maintenance therapy of reflux oesophagitis: results of a double-blind multi-centre study. Gastroenterology (1989) 96:A39.
50. HOWDEN CW, CASTELL DO, COHEN S et al.: The rationale for continuous maintenance treatment in reflux oesophagitis. Arch. Intern. Med. (1995) 155:1465-1471.
51. PIPER DW. A comparative overview of the adverse effects of antiulcer drugs. Drug Saf. (1995) 12:120-138.
52. 2-receptor antagonists. J. Clin. Pharmacol. (1995) 35:107-116.
53. DELHOTAL LANDES B, COURNOT A, VERMERIE N et al.: The effects of food and antacids on lansoprazole absorption and disposition. Eur Drug Metab. Pharmacokin. (1991) 3:315-320 (Special Issue).
54. ANDERSSON T, CEDERBERG C, EVARDSSON G, HEGGELUND A, LUNDBORG P: Effect of omeprazole treatment on diazepam plasma concentrations in slow versus normal rapid metabolisers of omeprazole. Clin. Pharmacol. Ther. (1990) 47:79-85.
55. ABELO A. ANDERSSON TB, ANTONSSON M, NAUDOT AK, SKANBERG I, WEIDOLF L: Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos. (2000) 28:266-272.
56. GUGLER R, JENSEN JC: Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology (1985) 89:1235-1241.
57. Study No. SH-QBE-0038: An interaction study between H 199/18 and warfarin in warfarin treated patients. Astra Zeneca. (1999) (Data on file).
58. FITTON A, WISEMAN L: Pantoprazole. A review of its pharmacological properties and therapeutic use in acid related disorders. Drugs (1996) 51:460-482.
59. GREEN JRB, TILDESLEY G, THEODOSSI A et al.: Omeprazole 20 to 40 mg once daily is more effective than ranitidine 300 to 600 mg daily in providing complete symptom relief and endoscopic healing in patients with reflux oesophagitis. Br. J. Clin. Res. (1995) 6:63-76.
60. BATE CM, GRIFFIN SM, KEELING PWN et al.: Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment. Pharmacol. Ther. (1996) 10:547-555.
61. VENABLES TL, NEWLAND RD, PATEL AC, HOLE J, WILCOCK C, TURBITT ML: Omeprazole 10 mg once daily, or ranitidine 150 mg twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand. J. Gastroenterol. (1997) 32:965-973.
62. HOLTMANN G, BYTZER P, BLUM AL: Clinical efficacy of a standard dose rabeprazole and a high dose omeprazole for the relief of GERD symptoms. Gastroenterology (2001) 120(Suppl. 3):62.
63. CASTELL DO, RICHTER JE, ROBINSON M, SONTAG SJ, HABER MM: Efficacy and safety of Lansoprazole in the treatment of erosive reflux esophagitis. Am. J. Gastroenterol. (1996) 91:1749-1757.
64. MEE AS, ROWLEY JL: Rapid symptom relief in reflux orsophagitis: a comparison of lansoprazole and omeprazole. Aliment. Pharmacol. Ther. (1996) 10:757-763.
65. FARLEY A, WRUBLE LD, HUMPHRIES TJ: Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double blind randomised clinical trial. Rabeprazole Study Group. Am. J. Gastroenterol. (2000) 95:1894-1899.
66. DELCHIER JC, COHEN G, HUMPHRIES TJ: Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. Scand. J. Gastroenterol. (2000) 35:1245-1250.
67. MOESSNER J, HOELSCHER AH, HERZ R, SCHNEIDER A: A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment. Pharmacol. Ther. (1995) 9:321-326.
68. ISKEDJIAN M, EINARDSON TR: Meta-analyses of cisapride, omeprazole and ranitidine in the treatment of GORD: implications for treating patient subgroups. Clin. Drug. Invest. (1998) 16:9-18.
69. CASTELL DO, KAHRILAS PJ, RICHTER JE et al.: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am. J. Gastroenterol. (2002) 97:575-583.
70. BASU KK, BALE R, WEST K, DECAESTECKER JS: Persistent acid reflux in patients with Barrett's oesophagus on proton-pump inhibitor. Eur. J. Gastroenterol. Hepatol. (2002) 14:1-6.
71. PEGHINI PL, KATZ PO, CASTELL DO: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology (1998) 115:1335-1339.
72. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology (2002) 122:625-632.
73. CHIBA N, DE GARA CJ, WILKINSON JM, HUNT RH: Speed of healing and symptomatic relief in Grade 2 - 4 gastroesophageal reflux disease: a meta-analysis. Gastroenterology (1997) 112:1798-1810.
74. 2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst. Rev. (2001):CD002095.
75. EDWARDS SJ, LIND T, LUNDELL L: Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment. Pharmacol. Ther. (2001) 15:1729-1736.
76. POYNARD T: Relapse rate of patients after healing of oesophagitis: a prospective study of alginate as self-care treatment for 6 months. French Co-operative Study Group. Aliment. Pharmacol. Ther. (1993) 7:385-392.
77. DENT J, YEOMANS ND, MACKINNON M et al.: Omeprazole versus ranitidine for prevention of relapse in reflux esophagitis. A controlled double blind trial of their efficacy and safety. Gut (1994) 35:590-598.
78. GOUGH AL, LONG RG, COOPER BT, Fosters CS, Garrett AD, Langworthy CH: Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment. Pharmacol. Ther. (1996) 10:529-539.
79. JANSEN J, HAECK PWE, SNEL P et al.: What is the preferred dose of lansoprazole in the maintenance therapy of reflux oesophagitis? The results of a Dutch multi-centre comparative trial. Eur. J. Gastroenterol. Hepatol. (1998) 10:A48/9.
80. CAOS A, MOSCOVITZ M, DAYAL Y, PERDOMO C, NIECESTRO R, BARTH J: Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rabeprazole Study Group. Am. J. Gastroenterology (2000) 95:3081-3088.
81. THJODLEIFSSON B, BEKER JA, DEKKERS C, BJAALAND T, FINNEGAN V, HUMPHRIES TJ: Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disaease: a double blind multicenter European trial. The European Rabeprazole Study Group. Dig. Dis. Sci. (2000) 45:845-853.
82. BATE CM, BOOTH SN, CROWE JP: Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut (1995) 36:492-498.
83. CARLING I, AXELSSON C, FORSELL H et al: Lansoprazole versus omeprazole in long-term maintenance treatment of reflux oesophagitis. A Scandinavian multicentre trial. Gut (1996) 39(Suppl. 3):182.
84. BALDI F, BARDHAN KD, BORMAN BC: Lansoprazole maintains healing in patients with reflux oesophagitis. Gastroenterelogy (1996) 110(Suppl.):55.
85. ESCOURROU J, DEPREZ P, SAGGIORO A, GELDOF H, FISCHER R, MAIER C: Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Aliment. Pharmacol Ther. (1999) 13:1481-1491.
86. EDWARDS SJ, LIND T, LUNDELL L: Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis. J. Drug Ass. (2002) 5:165-178.
87. SCHINDLBECK NE, KLAUSER AG, VODERHOLZER WA, MULLER-LISSNER SA: Empiric therapy for gastroesophageal reflux disease. Arch. Int. Med. (1995) 15:1808-1812.
88. FASS R, OFMAN JJ, GRALNEK IM et al.: Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch. Int. Med. (1999) 159:2161-2168.
89. TALLEY NJ, LAURITSEN K, TUNTURI-HIHNALA H et al.: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment. Pharmacol. Ther. (2001) 15:347-354.
90. KOIKE T, OHARA S, SEKINE H, IIJIMA. K, KATO K, TOYOTA T, SHIMOSEGAWA T: Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis. Alim Pharmacol. Ther. (2001) 15:813-820.
91. WU JC, CHANG FK, WONG SK, LEE YT, LEUNG WK, SUNG JJ: Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. Aliment. Pharmacol. Ther. (2002) 16:545-552.
92. LAINE L, SUGG J: Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am. J. Gastroenterol. (2002) 9:2992-2997.
93. HOLTMANN G, CAIN C, MALFERTHEINER P: Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology (1999) 117:11-16.
94. KUIPERS EJ, LUNDELL L, KLINKENBERG-KNOL EC et al.: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole of fundoplication. N. Engl. J. Med. (1996) 334:1018-1022.
95. LUNDELL L, MEITTINEN P, MYRVOLD HE et al.: Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology (1999) 117:319-326.
96. LUNDELL L: Gastro-oesophageal reflux disease and Helicobacter pylori or gastro-oeosphageal reflux disease from Helicobacter pylori? Eur. J. Gastroenterol. Hepatol. (2001) 13(Suppl. 1): S23-S27.
97. MARTIN RM, DUNN NR, FREEMANTLE S, SHAKIR S: The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br. J. Clin. Pharmacol. (2000) 50:366-372.
98. SVOBODA AC: Increasing concerns about chronic proton pump inhibitor use. J. Clin. Gastroenterol. (2001) 33:3-7.
99. HEUDEBERT GR, MARKS R, WILCOX CM, CENTOR RWM: Choice of long-term strategy for the management of patients with severe esophagitis: a cost utility analysis. Gastroenterology (1997) 112:1078-1086.
100. WATSON DI, JAMIESON GG: Antireflux surgery in the laparoscopic era. Br. J. Surg. (1998) 85:1173-1184.
101. GALMICHE JP, BRULEY DES VARANNES S: Endoluminal therapies for gastroephageal reflux disease. Lancet (2003) 361:1119-1121.
102. MAHMOOD Z, MCMAHON BP, ARFIN Q et al.: Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up. Gut (2003) 52:34-39.
103. TRIDAFILPOPOULOS G, DIBAISE JK, NOSTRANT TT, STOLMAN NH, ANDERSON PK, WOLFE MM: The Stretta procedure for the treatment of GERD: 6 and 12 months follow-up of the US open label trial. Gastrointest. Endosc. (2002) 55:149-156.
104. VAEZI MF, SINGH S, RICHTER J: Role of acid and duodenogastric reflux in esophageal injury: a review of animal and human studies. Gastroenterology (1995) 108:1897-1907.
105. SANDICK JW, VAN LANSCHOT JJ, TYTGAT GN, OFFERHAUS GJ, OBERTOP H: Barrett oesophagus and adenocarcinoma an overview of epidemiologic, conceptual and clinical issues. Scand J. Gastroenterol. (2001) 234(Suppl.):51-60.
106. PROVENZALE D, KEMP JA, ARORA S, WONG JB: A guide for surveillance for patients with Barrett's oesophagus. Am. J. Gastroenterol. (1999) 89:670-680.
107. HAMEETEMAN W, TYTGAT GN, HOUTHOFF HJ, VAN DEN TWEEL JG: Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology (1989) 96:1249-1256.
108. COOPER BT, NEUMAN CS, COX MA, IQBAL TH: Continuous treatment with omeprazole for up to 6 years in Barrett's oesophagus. Aliment. Pharmacol. Ther. (1998) 12:893-897.
109. SAMPLINER. RE: Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am. J. Gastroenterol. (1994) 89:1844-1848.
110. FITZGERALD RC, LASCAR R, TRIADAFILOPOULOS G: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. Aliment. Pharmacol. Ther. (2001) 15:269-276.
111. BASU KK, PICK B, BALE R, WEST KP, DECAESTECKER JS: Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut (2002) 51:776-780.
112. FALK GW: Gastroesophageal reflux disease and Barrett's esophagus. Endoscopy (2001) 33:109-118.